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Abstract
Background: Lung cancer is the number one cancer killer of both men and women in the United States. Three quarters
of lung cancer patients are diagnosed with regionally or distantly disseminated disease; their 5-year survival is only 15%.
DNA hypermethylation at promoter CpG islands shows great promise as a cancer-specific marker that would
complement visual lung cancer screening tools such as spiral CT, improving early detection. In lung cancer patients, such
hypermethylation is detectable in a variety of samples ranging from tumor material to blood and sputum. To date the
penetrance of DNA methylation at any single locus has been too low to provide great clinical sensitivity. We used the
real-time PCR-based method MethyLight to examine DNA methylation quantitatively at twenty-eight loci in 51 primary
human lung adenocarcinomas, 38 adjacent non-tumor lung samples, and 11 lung samples from non-lung cancer patients.
Results: We identified thirteen loci showing significant differential DNA methylation levels between tumor and non-
tumor lung; eight of these show highly significant hypermethylation in adenocarcinoma: CDH13, CDKN2A EX2, CDX2,
HOXA1, OPCML, RASSF1, SFPR1, and TWIST1 (p-value << 0.0001). Using the current tissue collection and 5-fold cross
validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung
adenocarcinoma from non-cancer lung with a sensitivity of 67–86% and specificity of 74–82%. DNA methylation of these
loci did not differ significantly based on gender, race, age or tumor stage, indicating their wide applicability as potential
lung adenocarcinoma markers. We applied random forests to determine a good classifier based on a subset of our loci
and determined that combined use of the same four top markers allows identification of lung cancer tissue from non-
lung cancer tissue with 94% sensitivity and 90% specificity.
Conclusion:  The identification of eight CpG island loci showing highly significant hypermethylation in lung
adenocarcinoma provides strong candidates for evaluation in patient remote media such as plasma and sputum. The four
most highly ranked loci, CDKN2A EX2, CDX2, HOXA1 and OPCML, which show significant DNA methylation even in
stage IA tumor samples, merit further investigation as some of the most promising lung adenocarcinoma markers
identified to date.
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Background
Lung cancer is expected to cause over 160,000 deaths in
2007 -killing more Americans than cancer of the prostate,
breast, colon, rectum and pancreas combined [1]. Lung
cancer is clinically classified into two classes: the aggres-
sive subtype small cell lung cancer (SCLC, ~13% of cases)
and non-small cell lung cancer (NSCLC, the remaining
~87%) [1]. NSCLC is histologically subdivided into four
major subtypes with distinct pathological and molecular
characteristics: adenocarcinoma, squamous cell lung can-
cer, large cell lung cancer and "other" (comprising neu-
roendocrine cancers, carcinoids etc.) [2]. Of these,
adenocarcinoma has recently surpassed squamous cell
lung cancer as the most common subtype in the United
States, accounting for approximately 40% of NSCLC [3].
The incidence of lung adenocarcinoma is on the rise in
many countries, in particular in women [4,5]. Adenocar-
cinoma is also the most common lung cancer subtype in
non- and previous smokers [6].
The 5-year survival of lung cancer patients is only 15%,
largely due to the fact that three quarters of lung cancer
patients are diagnosed when their disease has spread
regionally or distantly [7]. To make an impact on long
term survival, better strategies are needed for early detec-
tion. Prior experience with chest X-ray, sputum cytology,
and fiberoptic examination have failed to decrease lung
cancer patient mortality, although several recent strategies
show promise. Spiral computed tomography (spiral CT)
is one such approach. It allows detailed imaging of the
lung, and can detect very small lesions. Recent results
from the Early Lung Cancer Action Project (ELCAP) indi-
cate that this approach allows detection of early stage lung
cancer [8], but in this and other studies, non-cancerous
lesions far outnumber malignancies (less than 10% of
lesions are cancer). In addition, it is unclear whether the
early stage lung cancers identified by spiral CT represent
cancers that would ultimately progress and lead to death.
A recent analysis suggests spiral CT screening may not
reduce lung cancer mortality [9]. Molecular analyses of
plasma, sputum, and bronchial lavage fluids have also
shown promise as strategies for early detection, but these
methods still lack sensitivity [10]. If molecular markers
with high sensitivity and specificity for cancers that will
progress can be identified, such markers could be com-
bined with spiral CT to screen high-risk individuals,
allowing molecular detection and visualization of clini-
cally relevant early lesions. This would greatly increase the
chances of curative resection of lung cancer, while mini-
mizing unnecessary and potentially life-threatening pro-
cedures in patients with benign lesions.
Of the many potential molecular markers, DNA hyper-
methylation – an epigenetic alteration – shows great
promise. DNA hypermethylation occurs in all cancers, fre-
quently leading to gene silencing through methylation of
CpG-rich regions (CpG islands) near the transcriptional
start sites of genes [11]. In lung cancer patients, such
hypermethylation is quantitatively detectable in a variety
of samples ranging from tumor material to blood and
sputum [10]. However, to date the penetrance of DNA
methylation at any single locus has not been high enough
to provide great clinical sensitivity. Our focus is to
increase the repertoire of sensitive DNA hypermethylation
markers for lung cancer, and to compose a small panel of
molecular markers that could be used to detect lung can-
cer with high sensitivity and specificity. Given the his-
topathologic, clinical and molecular differences between
lung cancer subtypes, we believe that markers should be
developed individually for the major histological sub-
types. These markers can later be combined into a lung
cancer hypermethylation panel that can be used for detec-
tion of all lung cancers.
Because of its increasing frequency and its preponderance
in non- and previous smokers, we focused first on lung
adenocarcinoma (AD). Here we describe our evaluation
of 28 potential DNA methylation markers using primary
human lung adenocarcinoma samples. To ensure that
these markers detect cancer-specific  hypermethylation
changes, associated with histologically visible lung cancer
(allowing surgical resection), we compared the DNA
methylation profiles of the tumors with histologically
normal adjacent lung tissue (AdjNTL) from lung cancer
patients. We also examined non-tumor lung from non-
cancer patients (NTL).
Results
Ideal DNA hypermethylation markers for lung adenocar-
cinoma should show a high frequency of methylation in
tumors as well as DNA methylation levels that are signifi-
cantly elevated in tumor compared to non-tumor lung tis-
sue. Environmental exposures, such as those arising from
tobacco smoke, could lead to higher basal levels of meth-
ylation in non-tumor lung [12], which might affect the
background signal when any resulting markers are applied
to non-invasive molecular analyses of bodily fluids in the
future. To ensure the identification of markers that are
more highly methylated in adenocarcinoma even when
compared to heavily exposed but histologically cancer-
free lung, we used adjacent non-tumor lung (AdjNTL)
from lung cancer cases as our cancer-free comparison. The
AdjNTL sections were derived from separate, histologi-
cally verified cancer-free paraffin blocks. We also exam-
ined a number of non-tumor lung (NTL) samples from
patients operated for non-cancer reasons (emphysema,
lung collapse, etc.). Quantitative assessment of DNA
methylation levels allows a more detailed evaluation of
candidate DNA methylation markers, and of their suita-
bility for correctly identifying a cancer vs. non-cancer sam-Molecular Cancer 2007, 6:70 http://www.molecular-cancer.com/content/6/1/70
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ple. For this reason, we used the bisulfite conversion
based real-time PCR technique, MethyLight, to measure
DNA methylation in tumor and control tissues [13].
Twenty-eight loci were chosen for evaluation (Table 1).
The choice of loci was based on a prescreening of 114 loci
carried out on a collection of human lung cancer cell lines,
including 11 adenocarcinoma cell lines (unpublished
data). We also included many loci that appeared promis-
ing based on previous reports describing their DNA meth-
ylation in lung cancer or other cancers, so that all markers
of interest could be compared on one set of tissues using
a single technique and platform. Among others, the 28
loci included CpG islands in the promoters of tumor sup-
pressor genes and genes with important roles in cell cycle
regulation, DNA repair, and apoptosis (Table 1).
The results of the DNA methylation analyses for the 28
loci in 51 AD, 38 AdjNTL and 11 NTL samples are shown
in Fig. 1. DNA methylation, expressed as the percentage
methylated reference (PMR [14]) is visualized by color
coding. Comparison of AD in Fig. 1 panel A with AdjNTL
in panel B shows that a number of loci are more heavily
methylated in AD. The effect appears to be even more pro-
nounced when AD is compared to NTL from non-cancer
patients. Although the exposure history of these NTL sam-
ples is unknown, their generally lower DNA methylation
levels emphasize that these samples may not be the best
controls when searching for loci that show cancer-specific
hypermethylation. Interestingly, for one locus, LZTS1
(leftmost locus in Fig. 1), the DNA methylation pattern
appeared to be reversed; NTL showed the highest level of
DNA methylation, while AD samples were least methyl-
ated.
We applied two-dimensional hierarchical clustering to
examine the relationship between the loci and the tumor
and non-tumor lung samples (Fig 2; VHL was omitted
Table 1: Gene name and function of the 28 loci studied
HUGO acronyma Gene Nameb Functionc
APC adenomatosis polyposis coli Tumor suppressor.
ATM ataxia telangiectasia mutated Tumor suppressor. DNA damage and cell cycle control.
CDH1 cadherin 1, type 1, E-cadherin (epithelial) Involved in cell-cell adhesions, mobility and proliferation.
CDH13 cadherin 13, H-cadherin (heart) Cell-cell adhesions.
CDKN2A EX2 cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits 
CDK4)
Tumor suppressor. Cell cycle control. Involved in 
proliferation and apoptosis.
CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) Cell cycle control.
CDX2 caudal type homeobox transcription factor 2 Transciptional regulation. Involved in differentiation.
CHFR checkpoint with forkhead and ring finger domains Cell cycle control. Involved in signaling.
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 Electron transport pathway. Involved in development.
ESR1 estrogen receptor 1 Nuclear hormone receptor. Involved in the regulation of 
gene expression and affect proliferation and differentiation.
HMGA1 high mobility group AT-hook 1 Involved in the transcription regulation.
HOXA1 homeobox A1 Transcription factor. Involved in development.
LZTS1 leucine zipper, putative tumor suppressor 1 Involved in the regulation of cell growth. Cell cycle control 
and proliferation. May act as tumor suppressor.
MGMT O-6-methylguanine-DNA methyltransferase DNA repair.
MT1A, MT2A metallothionein 1A, 2A Bind heavy metals.
OPCMLd opioid binding protein/cell adhesion molecule-like Involved in cell contact
PGR progesterone receptor Involved in the regulation of gene expression and cellular 
proliferation and differentiation.
PTEN phosphatase and tensin homolog Tumor suppressor. Involved in cell cycle progression and 
cell survival. Involved in cell migration and cell spreading.
RASSF1 Ras association (RalGDS/AF-6) domain family 1 Potential tumor suppressor. Invovled in apoptosis, 
proliferation, cell cycle progression.
SFRP1, SFRP4, SFRP5 secreted frizzled-related protein 1, 4, 5 Role in regulating cell growth and differentiation and 
proliferation. Involved in development.
SLC6A20 solute carrier family 6 (proline IMINO transporter), member 20 Sodium- and chloride-dependent transporter.
SOCS4 suppressor of cytokine signaling 4 Involved in signal transduction.
SYK spleen tyrosine kinase Involved in B cell response.
TWIST1 twist homolog 1 (acrocephalosyndactyly 3; Saethre-Chotzen 
syndrome) (Drosophila)
Transcription factor. Involved in differentiation.
VHL von Hippel-Lindau tumor suppressor Involved in transcriptional repression.
aHuman Genome Organization nomenclature
bApproved gene name from Human Genome Organization website http://www.genenames.org/
cGene function from GeneCards website http://www.genecards.org/index.shtml
dMethyLight amplicon also targets the HNT CpG islandMolecular Cancer 2007, 6:70 http://www.molecular-cancer.com/content/6/1/70
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Graphic representation of PMR values obtained for 28 loci in AD (A), AdjNTL (B) and NTL (C) Figure 1
Graphic representation of PMR values obtained for 28 loci in AD (A), AdjNTL (B) and NTL (C). Samples are indicated at the 
left, loci at thetop. PMR values have been categorized as colored boxes denoting no detectable DNA methylation (blue), DNA 
methylation below the median of all positive samples of each locus (yellow), and DNA methylation equal to or above the 
median (red). The black bar at bottom indicates loci showing statistically significant differences in DNA methylation levels 
between tumor and non-tumor lung.
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Two-dimensional hierarchical clustering of samples and loci based on DNA methylation data Figure 2
Two-dimensional hierarchical clustering of samples and loci based on DNA methylation data. In the center, DNA methylation 
levels are indicated by a color gradient, with the highest DNA methylation levels for each locus indicated in red and the lowest 
in deep blue. The Ward hierarchical clustering method was used to categorize between cancer and non-tumor samples. Sample 
IDs are indicated on the left, with AD samples in red, AdjNTL samples in black, and NTL samples in blue. The relationship of 
samples is indicated at right in the same color schematic as the labels. At bottom, the relationship of the loci is indicated. Note 
that all eight of the most significant loci cluster at bottom right.
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because it showed no DNA methylation in any samples).
All but one of the tumor samples clustered together in a
major branch of the dendrogram, while the majority of
non-tumor lung samples grouped in a separate cluster.
Nine loci, CDH13, SFRP1, OPCML, TWIST1, SFRP5,
CDKN2A EX2, CDX2, HOXA1 and RASSF1, clustered
together (bottom right), showing heavier DNA methyla-
tion in the tumor samples.
We next analyzed the statistical significance of the differ-
ences in DNA methylation levels for individual markers
and different combinations of tissue samples (Table 2):
AD vs. all NTL samples, AD vs. AdjNTL, and AD vs. paired
AdjNTL (32 of the 38 AdjNTL samples were derived from
the AD patients in Fig. 1A). The paired AdjNTL form an
exquisite control for the cancer-specific nature of the
observed DNA methylation changes, as each of these sam-
ples conforms to its tumor sample in patient age, environ-
mental exposure, and genetic background. To avoid
assigning statistical significance to spurious associations,
we incorporated a multiple comparisons threshold for
those loci that at time of analysis lacked any prior data
suggesting they might be hypermethylated in lung adeno-
carcinoma (Table 2, before-last column, [15] see Materials
and Methods for details). Thirteen of the analyzed loci
showed statistically significant differences in DNA meth-
ylation when AD samples were compared to all NTL sam-
ples: OPCML, CDX2, HOXA1, CDKN2A EX2, SFRP1,
CDH13, TWIST1, LZTS1, RASSF1, SFRP4 and 5, ESR1, and
CDH1. All of these except CDH1 remained significant
when AD samples were compared to AdjNTL, while all
except LZTS1 remained significant in the comparison of
Table 2: Frequency and median PMR values of AD, Adj NTL and NTL tissues for 28 loci
HUGOa Frequencyb Medianf p-valueg
ADc 
n = 51
Adj NTLd 
n = 38
NTLe 
n = 11
AD
 n = 51
Adj NTL
n = 38
NTL
n = 11
AD vs 
All NTL
AD vs 
AdjNTL
AD vs 
matched NTL
BH-MC 
Thresholdh
Importance 
Measurei
OPCML 98 79 36 107.15 8.93 10.02 9E-15 8E-13 2E-10 0.0025 7.38
CDX2 100j 66 9 43.97 3.40 0.12 4E-13 2E-10 8E-10 0.0050 3.49
H O X A 1 9 47 13 6 1 6 0 . 0 0 4 . 9 0 0 . 1 2 2E-12 2E-10 2E-10 N/A 8.52
CDKN2A EX2 100 100 82 191.07 46.17 27.39 6E-12 4E-10 1E-10 N/A 5.80
SFRP1 94k 87 36 132.93 10.01 4.78 1E-10 2E-08 1E-09 0.0075 2.62
CDH13 78 45 0 39.65 4.95 78.05 4E-08 9E-07 2E-08 N/A 2.14
TWIST1 82 66 9 392.16 6.87 8.03 1E-07 8E-06 1E-07 0.0100 2.77
LZTS1 100 100 100 107.75 170.95 210.95 5E-06 0.0003 0.0262 0.0125 1.52
RASSF1 69k 58 9 92.53 0.86 5.45 6E-05 0.0010 1E-07 N/A 1.83
SFRP4 67k 42 9 3.25 1.03 8.71 0.0005 0.0052 0.0086 0.0150 0.39
SFRP5 90k 92 45 14.38 5.78 4.59 0.0005 0.0095 0.0010 0.0175 0.72
ESR1 49k 32 9 5.72 1.29 0.63 0.0049 0.0283 0.0007 N/A 0.33
CDH1 94 89 55 17.62 12.74 10.22 0.0092 0.0686 0.0151 N/A 0.51
SLC6A20 25 11 9 7.81 0.38 154.45 0.0426 0.0569 0.0244 0.0200 0.10
PGR 14 5 0 59.92 6.95 N/A 0.0850 0.1753 0.4375 0.0225 0.08
MT1A 100 100 100 104.45 108.58 112.44 0.2276 0.4283 0.7422 0.0250 0.84
MT2A 88 76 55 12.31 12.22 15.48 0.2650 0.4568 0.4622 0.0275 0.37
ATM 75 68 27 0.16 0.19 0.03 0.2954 0.9498 0.5131 0.0300 0.07
PTEN 29 26 0 1.21 0.85 N/A 0.3319 0.7976 0.8077 0.0325 0.07
SYK 29 24 18 0.42 0.15 3.34 0.4314 0.5002 0.8904 0.0350 0.07
CDKN2B 98 97 91 8.29 10.05 8.48 0.4400 0.2422 0.5335 0.0375 0.44
CYP1B1 29 26 18 1.80 1.26 0.13 0.4481 0.6565 0.1454 0.0400 0.11
CHFR 8 5 0 0.49 1.65 N/A 0.4560 0.6677 1.0000 0.0425 0.04
APC 80 97 82 15.10 4.60 10.81 0.5999 0.5923 0.0394 N/A 1.89
SOCS4 12j 13 18 0.25 1.70 85.45 0.6040 0.7637 0.3125 0.0450 0.13
MGMT 16 18 0 224.53 9.22 N/A 0.7141 0.8988 0.2031 N/A 0.07
HMGA1 20j 18 27 0.19 0.02 0.12 0.9642 0.7645 0.6221 0.0475 0.00001
VHL 0 0 0 N/A N/A N/A 1.0000 1.0000 1.0000 0.0500 0
a HUGO, Human Genome Organization nomenclature sorted by AD vs All NTL p-value with the most significant at the top.
bPercentage of samples with positive methylation value.
cAD, Adenocarcinoma
dAdj NTL, Adjacent non-tumor lung from adenocarcinoma patients
eNTL, Non-tumor lung from non-cancer patients
fMedian percent methylated reference calculated from positive methylation values
gStatistically significant numbers are highlighted in bold; AD vs. all NTL and AD vs. AdjNTL: Wilcoxon rank sum test; AD vs. matched NTL: 
Wilcoxon signed rank test
hBH-MC threshold, Benjamini- Hochberg multiple comparison threshold p-value
iImportance Measure based on random forest analysis
jn = 50
kn = 49Molecular Cancer 2007, 6:70 http://www.molecular-cancer.com/content/6/1/70
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AD to paired AdjNTL. Because DNA methylation of LZTS1
is reduced in tumors it is not a candidate for a positive
lung adenocarcinoma marker and it was not studied fur-
ther at this time. APC methylation was found to be statis-
tically significantly different only when paired tumor and
non-tumor lung samples were compared. This suggests
that basal DNA methylation is high but variable at this
locus; elevated DNA methylation in tumors is likely
masked by interpatient variability and only becomes visi-
ble when samples from the same patient are compared.
Indeed, Waki and coworkers have observed frequent DNA
methylation of APC in non-cancer lung and other organs
[16].
Of the thirteen significant loci, OPCML, CDX2, HOXA1,
CDKN2A EX2, SFRP1, CDH13, TWIST1 and RASSF1 show
considerable promise as cancer-specific DNA methylation
markers, exhibiting highly significant hypermethylation
in tumors compared to paired non-tumor tissues (p ≤ 1 ×
10-7, Table 2). All eight of these loci grouped together in
the hierarchical clustering (Fig. 2). The ability of the top
four candidates, CDKN2A EX2, CDX2, HOXA1 and
OPCML (all p < 1 × 10-9), to individually identify lung
cancer samples was next evaluated. Fig. 3 shows the distri-
bution of PMR values in the examined sample collection.
Note that for all four markers, the mean value in non-
tumor lung from non-cancer patients is lower than that of
adjacent non-tumor lung from lung cancer patients. This
emphasizes the importance of using histologically normal
tissue adjacent to lung cancer for comparison; such tissue
may show higher basal DNA methylation levels while
appearing histologically normal, and should be used for
comparison with lung cancer tissue to ensure identifica-
tion of cancer-specific  markers. While all four markers
show increased DNA methylation in adenocarcinoma
compared to adjacent non-tumor tissue, the spread of
DNA methylation levels differs, which would affect their
sensitivity and specificity in future detection strategies.
The marker potential of quantitative markers is frequently
presented in the form of a receiver operating characteristic
(ROC) curve, in which sensitivity vs. 1-specificity at all
possible cut-off values is plotted. While these DNA meth-
ylation markers are ultimately intended for the non-inva-
sive analysis of patient bodily fluids, a preliminary
indication of their potential to sensitively and specifically
detect cancer could be obtained by plotting ROC curves
using the PMR values from the tumor vs. adjacent non-
tumor samples. Fig. 4 shows that the area under the curve
(AUC, and indicator of marker performance that would
be 1 for a marker showing 100% specificity and sensitivty)
is 0.87–0.95 for the four top loci.
Despite the promising AUC values, the sensitivity and spe-
cificity of these top four markers, used individually and
determined using the current sample collection in a five-
fold cross-validation, was limited: 67–86% and 74–82%
respectively. This supports the notion that DNA hyper-
methylation markers are best used in the form of a panel.
Because of the costs associated with quantitative molecu-
lar analyses, it would be important to limit the number of
markers included in the panel. To determine which com-
binations of markers would be most effective to correctly
identify tumor vs. non-tumor samples, we fit a random
forest classifier to the data set, using 87 samples and 28
variables (2 AD samples with missing PMR data were
omitted, resulting in 49 AD vs. 38 AdjNTL). Using boot-
strap samples of the data, we grew a forest of 30,000 trees.
Splits were determined using a random sample of five var-
iables and trees were grown until there was only one
observation in each leaf. Utilizing all 28 loci, we estimated
a sensitivity of 92% and a specificity of 95%. Using the
Gini index from the random forest classifier (last column,
Table 2) to measure locus importance, we restricted our
analysis to the most highly ranked variables. Reducing the
locus number to 13 did not affect sensitivity and specifi-
city, and limiting our markers to the top-ranked four
(HOXA1, OPCML, CDKN2AEX2 and CDX2, which were
also the most significant based on our statistical analysis)
resulted in a sensitivity of 94% and a specificity of 90%.
Thus, these four markers appear to be highly promising
DNA hypermethylation markers for development into
non-invasive molecular markers of lung adenocarcinoma,
through examination of DNA shed into bodily fluids such
as sputum, bronchioalveolar lavage, or blood.
For candidate hypermethylation markers of lung adeno-
carcinoma, two important questions arise. First, are these
markers hypermethylated in cancer samples irrespective
of the subject's age, gender and racial/ethnic background?
And secondly, are these markers hypermethylated even in
the earliest stages of lung adenocarcinoma? While the
population analyzed in the current study is small, we rea-
soned that an indication of the potential of our top four
markers to broadly identify lung adenocarcinoma might
be obtained. To address the first question, we assessed cor-
relations to age and determined whether each of the four
markers showed statistically significant hypermethylation
in tumor vs. adjacent normal tissues in men, women, and
all four racial/ethnic groups. We found no correlation of
methylation of CDKN2A EX2, CDX2, HOXA1 and
OPCML with the age. In addition, all four markers
remained significantly hypermethylated in tumor vs.
AdjNTL when subjects were stratified by gender or by eth-
nic group (p < 0.05) (Table 3). The only exception was
CDKN2A EX2 methylation in Asian subjects (p = 0.11),
which may be related to the small sample size but will
need to be further explored.
To address the second question, we determined whether
each of the four markers was significantly hypermethyl-Molecular Cancer 2007, 6:70 http://www.molecular-cancer.com/content/6/1/70
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ated in early and later stage tumors, using paired samples
(Table 3). We examined stages IA and IB individually, but
grouped stages IIA, IIB, and IIIA (only one paired sample
was available for IIA and IIIA, and none for stage IIIB).
Importantly, all four markers were significantly hyper-
methylated in stage IA cancers. Only CDKN2A EX2 hyper-
methylation was significant in stage IB tumors, but this
could be due to the small number of paired samples (n =
6). All markers were also significantly hypermethylated in
later stage lung adenocarcinoma (Stages IIA-IIIA). These
analyses indicate that the top four markers show high
potential for identification of lung adenocarcinoma, even
in its earliest stages, an important characteristic if these
markers are to be used for early detection.
To determine whether any of the four top markers might
have prognostic implications, we determined whether
there was any relationship between their DNA methyla-
tion level and survival. We found no significant associa-
tion between DNA methylation and survival for the four
loci, or any of the other 24 loci studied (data not shown).
Discussion
Based on the results of our analyses, four loci that are very
strong candidates for a DNA methylation panel aimed at
early lung adenocarcinoma detection have been identi-
fied: CDKN2A EX2, CDX2, HOXA1 and OPCML.
CDNK2A, also referred to as p16INK4a, encodes an impor-
tant cell cycle regulator that is frequently inactivated in
cancer. CDKN2A is one of the first tumor suppressor
genes found to be methylated in a variety of cancers,
including lung cancer [17]. It is one of the most widely
studied hypermethylated loci, and methylation of its pro-
moter CpG island appears to be a very early event in the
development of non-small cell lung cancer (recently
reviewed in [10]). In fact, methylation of the CDKN2A
promoter CpG island has been observed in the sputum of
subjects at risk for lung cancer 3 years prior to diagnosis
[18] and in the sputum of asymptomatic heavy smokers
[19]. A recent analysis of prospectively collected sputum
showed CDKN2A methylation in 39% of cases and 25%
of controls; methylation of this gene was associated with
an elevated risk of lung cancer [20]. It is thought that DNA
methylation observed in the sputum is indicative of field
cancerization of the airways and not necessarily a symp-
tom of a present cancer [20]. Our goal was to identify can-
cer-specific markers, not risk markers. We had evaluated
DNA methylation of the CDKN2A promoter CpG island
as a cancer indicator, but found substantial DNA methyl-
ation in AdjNTL, and no significant difference between
The distribution of PMR values by group Figure 3
The distribution of PMR values by group. Log-transformed PMR values for AD, AdjNTL and NTL are shown. The mean is 
shown by the wide horizontal line, and the top and bottom of the diamond indicate a 95% normal confidence interval for the 
sample mean.
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AdjNTL and cancer (data not shown). Based on the can-
cer-specific hypermethylation of the CDKN2A exon 2
CpG island observed in colorectal and bladder cancers
[21,22], we tested this downstream island instead. We
established that its level of DNA methylation is a strong
indicator of lung adenocarcinoma. While substantial
methylation at the exon 2 CpG island is detected in histo-
logically normal AdjNTL, by comparison, DNA methyla-
tion in adenocarcinoma is highly significantly elevated (p
≤ 1 × 10E-10). The detection of CDKN2A methylation in
a high fraction of lung cancer patient plasma samples
bodes well for its application to non-invasive detection
[23]. Two groups reported an association of DNA methyl-
ation of CDKN2A with poor survival in adenocarcinoma/
NSCLC patients [24,25], while Divine et al (2005), like us,
reported no such association [12]. The differences
between the obtained results might be due to the exami-
nation of a different CpG island or a different population.
DNA methylation of HOX genes, encoding homeobox
transcription factors involved in embryogenesis and dif-
ferentiation, had recently been observed in lung adeno-
carcinoma and squamous cell lung cancer. In an analysis
of eight adenocarcinomas and matching adjacent lung,
substantial DNA methylation of the HOXA and D clusters
was observed [26]. Five cancer samples showed DNA
methylation of HOXA1, while only one AdjNTL sample
was methylated at this locus. In a different study, analysis
of a stage I adenocarcinoma and squamous cell lung car-
cinoma showed DNA methylation of the HOX clusters,
and examination of the HOXA and D clusters in more
detail in squamous cell cancers and control tissue indi-
cated a DNA methylation frequency of 45–80% for
HOXA7-9, but methylation of HOXA1 was limited [27].
Neither of these studies examined a large number of ade-
nocarcinomas, nor were quantitative techniques used.
Here we demonstrate that HOXA1 is a very promising
DNA methylation marker for lung adenocarcinoma. We
Receiver operating characteristic curves for the four top markers Figure 4
Receiver operating characteristic curves for the four top markers. All AD and AdjNTL lung samples for which there was com-
plete DNA methylation data were used for the analysis.
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have also observed DNA methylation of additional HOX
genes (unpublished studies), but HOXA1 appears to be
particularly informative.
OPCML, encoding an opioid-binding cell adhesion mole-
cule, has been shown to be frequently methylated in ovar-
ian cancer [28]. Given that opioids have demonstrated
growth inhibitory and pro-apoptotic effects in lung cancer
cells [29-31], it is perhaps not surprising that the OPCML
Table 3: Performance of top four markers in samples based on gender, race/ethnicity and stage
Median PMR, Tumor Tumor Median PMR, AdjNTL p-valuea
GENDER
Male n = 28 n = 19
CDKN2A EX2 199.44 51.88 5.0E-06
CDX2 28.40 4.78 2.0E-05
HOXA1 139.51 5.06 4.6E-05
OPCML 76.62 11.27 1.6E-06
Female n = 14 n = 10
CDKN2A EX2 189.16 38.64 1.3E-04
CDX2 114.71 3.15 4.0E-06
HOXA1 188.13 1.34 3.1E-06
OPCML 154.32 5.36 3.1E-06
RACE
White Hispanic n = 14 n = 10
CDKN2A EX2 165.47 37.52 6.0E-04
CDX2 39.49 1.98 2.0E-04
HOXA1 52.98 1.75 7.7E-03
OPCML 142.56 8.17 6.0E-04
White Non-Hispanic n = 14 n = 10
CDKN2A EX2 314.35 38.00 5.0E-04
CDX2 110.73 4.78 0.001
HOXA1 231.66 4.90 4.6E-05
OPCML 179.79 6.54 4.7E-05
Black n = 11 n = 7
CDKN2A EX2 194.91 51.88 0.015
CDX2 129.96 9.11 0.024
HOXA1 128.52 6.16 0.011
OPCML 91.15 14.29 0.005
Asian n = 6 n = 4
CDKN2A EX2 145.56 39.81 0.11
CDX2 24.28 1.78 0.023
HOXA1 117.49 0.99 0.014
OPCML 88.81 4.67 0.014
STAGEb
Stage IA n = 12 n = 12
CDKN2A EX2 182.57 47.28 4.9E-04
CDX2 99.71 3.15 4.9E-04
HOXA1 143.06 3.25 0.001
OPCML 189.43 7.65 4.9E-04
Stage IB n = 6 n = 6
CDKN2A EX2 190.67 61.00 0.031
CDX2 20.62 13.36 0.31
HOXA1 78.98 2.15 0.063
OPCML 76.62 15.16 0.063
Stage IIA/IIB/IIIAc n = 10 n = 10
CDKN2A EX2 208.05 39.81 0.01
CDX2 83.22 1.78 0.002
HOXA1 180.18 6.16 0.002
OPCML 178.54 8.25 0.002
ap-value calculated by Mann-Whitney for gender and race and Wilcoxon signed rank test for stage, in which paired adjacent samples were used. 
Italics: p > 0.05; b Paired adjacent samples; c Only one paired sample was available for stages IIA and IIIA and none for IIIB, hence IIA/IIB/IIIA were 
pooled.Molecular Cancer 2007, 6:70 http://www.molecular-cancer.com/content/6/1/70
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promoter CpG island might be a target for DNA methyla-
tion in lung cancer. Very recently, high throughput DNA
methylation profiling of 11 lung adenocarcinomas and
control lung identified a number of CpG dinucleotides
methylated in the cancer samples [32]. One probe identi-
fied DNA methylation in the area covered by the OPCML
probe used here. Although the OPCML locus was not
studied in detail in the Bibikova study, the observed meth-
ylation supports the idea that OPCML is a strong candi-
date marker in lung adenocarcinoma.
CDX2, another homeobox transcription factor, had been
described to be methylated in squamous esophageal can-
cer [33] and colorectal carcinoma [34], but to our knowl-
edge, its DNA methylation in lung cancer has never been
examined. We find it to be methylated in 100% of lung
adenocarcinomas, showing a 10-fold higher median
methylation than AdjNTL tissue (Table 2).
Because our primary goal is marker development, here we
focused only on whether loci showed consistent hyper-
methylation. Whether or not this hypermethylation
results in gene inactivation is not relevant for the use of
these loci as DNA methylation markers, and was not
determined. However, the biological consequences of the
observed hypermethylation would also be worth investi-
gating. While each of the four top-ranked loci is of interest
as a DNA methylation marker, it is as a panel that they
promise to be most powerful. To our knowledge, we are
the first to examine CDKN2A EX2, CDX2, HOXA1 and
OPCML in combination. The fact that this marker set
allows identification of cancer specimens in the current
tissue collection with a substantially higher sensitivity and
specificity than any previously identified single markers
underlines the importance of developing suitable marker
panels.
Conclusion
From a starting panel of 28 DNA methylation loci, we
have identified 13 that show statistically significant meth-
ylation differences between lung adenocarcinoma and
non-cancer lung tissue. Of these, 8 show highly significant
differences. The four most significant markers also ranked
as the top four to be used in a marker panel, as determined
by a random forest approach. Thus, we suggest that
CDKN2A EX2, CDX2, HOXA1 and OPCML are the top
candidates from the 28 tested, and should be validated as
DNA methylation markers for lung adenocarcinoma.
These validations should consist of examining a suffi-
ciently large number of new subjects representing both
genders and all four major ethnic/racial subgroups in the
United States (Whites of non-Hispanic and Hispanic
descent, Blacks, and Asians), as well as early and late stage
cancer. Such studies are currently ongoing. Our analyses
of the present sample collection, which contains modest
numbers of representatives from all these groups, is very
encouraging as they suggest that the markers function
independently of subject age, gender or ethnic subgroup,
and are positive in early stage cancer.
The next step would entail the exploration of different
methods to measure these markers non-invasively in early
stage lung cancer patients. Potential "remote" media to be
considered are sputum, bronchioalveolar lavage, and
blood plasma, all of which we are in the process of collect-
ing for examination. The ability of our four-marker panel
to clinically detect lung cancer with high sensitivity and
specificity will depend on many factors. A loss of sensitiv-
ity might be foreseen due to the small amounts of DNA
shed into the blood of each patient, but at the same time,
an increase in specificity might be expected if tumor DNA
is shed more readily into the bloodstream than DNA from
adjacent histologically normal tissue.
To our knowledge, CDKN2A EX2, CDX2, HOXA1 and
OPCML constitute the strongest lung adenocarcinoma
DNA methylation markers identified to date, and we are
working on further evaluations of their potential with
great anticipation.
Methods
Study subjects
Lung adenocarcinoma and when available adjacent non-
tumor lung was obtained from archival paraffin blocks
from 51 subjects who had been treated at three Los Ange-
les hospitals: the Los Angeles County Hospital, the USC
University Hospital and the Norris Comprehensive Can-
cer Center. Clinical information was missing for 5
patients. Of the rest, 28 were male and 18 were female, 14
were White of non-Hispanic descent, 14 White of His-
panic descent, 11 were Black, and 7 were of various Asian
origins. Ages ranged from 37–82 years old at time of sur-
gery (median: 58 years old). For 32 of these cases, a sepa-
rate paraffin block containing histologically verified
cancer-free lung was available. These adjacent non-tumor
lung samples were supplemented with 6 additional can-
cer-free archival samples from lung cancer patients for
which the tumor block was unavailable, and 11 archival
non-tumor lung samples from patients operated for non-
cancer reasons, such as pneumothorax or emphysema. All
studies were institutionally approved by the University of
Southern California Institutional Review Board (IRB# HS-
016041, HS-06-00447), and the identities of patients
were not made available to laboratory investigators.
Tissue samples and DNA extraction
Hematoxylin and eosin-stained slides were reviewed by
an experienced lung pathologist (MNK) to support the
original classification of the tumor and to select optimal
tumor and non-tumor areas of the specimens. DNA wasMolecular Cancer 2007, 6:70 http://www.molecular-cancer.com/content/6/1/70
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extracted from microdissected tumor and non-tumor lung
samples via proteinase K digestion [35]. Briefly, cells were
lysed in a solution containing 100 mmol/L Tris-HCl (pH
8.0), 10 mmol/L EDTA (pH 8.0), 1 mg/mL proteinase K,
and 0.05 mg/mL tRNA and incubated at 50°C overnight.
The DNA was bisulfite converted as previously described
[13].
DNA methylation analysis
DNA methylation analysis was done by MethyLight as
previously described [14]. Primer and probe sequences
were as described [14,36,37]. In addition to primers and
probe sets designed specifically for the gene of interest, an
internal reference primer and probe set designed to ana-
lyze Alu repeats (Alu) was included in the analysis to nor-
malize for input DNA [38]. The percentage methylated
reference (PMR) was calculated as the GENE:reference
ratio of a sample divided by the GENE:reference ratio of in
vitro  methylated (SssI-treated) human white blood cell
DNA and multiplying by 100 [14]. Occasionally, PMR val-
ues over 100 were observed. This can happen when genes
are very heavily methylated in the cancer sample, while
the SssI-treated sample (in spite of extensive in vitro DNA
methylation) is not fully methylated at that locus. This
does not affect the significance of the loci identified in this
study, as the same batch of SssI-treated DNA was used
throughout the study.
Statistical analyses
PMR values of AD were compared to AdjNTL and NTL
lung as continuous variables by means of the Wilcoxon
rank sum test. For the comparison of paired AD and
AdjNTL samples from the same patients, the Wilcoxon
signed rank test was used. To control the false discovery
rate at 5%, a multiple comparisons threshold was set. It
was only applied to those 20 loci for which no previous
information supporting a hypothesis of DNA methylation
in lung AD was available [15]. Receiver operating charac-
teristic (ROC) curves were plotted using the AD vs. all
AdjNTL lung PMR values and JMP 6.0 software (SAS Insti-
tute, Cary, NC). The distribution of PMR values by group
(AD, AdjNTL and NTL) were shown using log-trans-
formed data in JMP 6.0. The two-dimensional hierarchical
clustering was carried out using JMP 6.0 and log-trans-
formed PMR values. VHL, which was negative in all spec-
imens, was omitted from the clustering analysis.
Associations between age, gender and race of AD cases
were tested by dichotomizing the subjects either by the
presence/absence of DNA methylation, or, if the samples
were frequently methylated, by the median of all positive
PMR values. All statistical tests were two-sided.
To determine which combinations of markers would be
most effective to correctly identify tumor vs. non-tumor
samples, we fit a random forest classifier to the data set,
using the R programming language (v 2.5 [39]) and 87
samples and 28 variables (2 AD samples with missing
PMR data were omitted, resulting in 49 AD/38 AdjNTL).
Using bootstrap samples of the data, we grew a forest of
30,000 trees. Splits were determined using a random sam-
ple of five variables and trees were grown until there was
only one observation in each leaf. We determined error
rates using the observations that were not used to generate
the trees. For each observation, its outcome was predicted
by having the majority vote from the trees that were gen-
erated without the original data point in their bootstrap
sample. These predicted values were compared against the
true tissue type to estimate prediction error.
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